GSK plc (LON:GSK) Given Average Rating of “Moderate Buy” by Analysts

Shares of GSK plc (LON:GSK) have been given an average rating of “Moderate Buy” by the seven research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is GBX 1,805.83 ($22.40).

Several research firms have recently commented on GSK. Berenberg Bank lowered their target price on GSK from GBX 1,820 ($22.58) to GBX 1,600 ($19.85) and set a “buy” rating for the company in a report on Friday, November 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Tuesday, January 7th.

Insider Buying and Selling at GSK

In other news, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was purchased at an average cost of GBX 1,315 ($16.31) per share, with a total value of £19,725 ($24,469.67). 1.61% of the stock is currently owned by corporate insiders.

GSK Stock Down 2.5 %

LON:GSK opened at GBX 1,443 ($17.90) on Friday. The firm has a market capitalization of £58.87 billion, a PE ratio of 1,276.99, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The stock has a 50 day moving average of GBX 1,356.75 and a 200-day moving average of GBX 1,457.45. GSK has a 52 week low of GBX 1,282.50 ($15.91) and a 52 week high of GBX 1,823.50 ($22.62). The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04.

GSK (LON:GSK) last posted its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a return on equity of 33.30% and a net margin of 12.83%. Analysts predict that GSK will post 175.980975 EPS for the current year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.